Format

Send to

Choose Destination
Oncotarget. 2018 Jun 1;9(42):26659-26669. doi: 10.18632/oncotarget.25426. eCollection 2018 Jun 1.

CD73 expression and clinical significance in human metastatic melanoma.

Author information

1
Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland.
2
Department of Oncology, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
3
Institute of Social and Preventive Medicine (IUMSP), University Hospital, Lausanne, Switzerland.
4
Anatomopathology Department, Centre Léon Bérard, Lyon, France.
5
Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
6
Université Claude Bernard Lyon 1, Centre de recherche en cancérologie de Lyon, Lyon, France.
7
Department of Innovation and Translational Research, Centre Léon Bérard, Lyon, France.

Abstract

Background:

CD73 is an ectoenzyme involved in the production of adenosine. It exerts immunosuppressive and protumoral roles and has emerged as a potential immuno-oncology target.

Results:

CD73 expression was detected in TC in 54% of melanoma metastases, involving < 50% TC in the majority of the cases, with variable intensity. CD73 expression was significantly associated with a lower Breslow's depth of the primary lesion and was more frequent in patients having received prior non-surgical therapies. In an adjusted analysis, CD73 expression in TC (H-score > 37.5 or intensity > 1) significantly correlated to decreased overall survival (OS) from biopsy. Of the samples containing TIMC, 35% presented CD73+ TIMC. Highly infiltrated tumors were more likely to contain CD73+ TIMC. CD73 expression in TIMC (percentage ≥1%) significantly correlated with improved OS from biopsy.

Conclusions:

Immunohistochemistry detected CD73 expression in more than half of metastatic melanomas. While CD73 expression in TC significantly correlated with decreased OS, CD73 expression in TIMC significantly associated with improved OS. These results encourage the study of anti-CD73 therapies for metastatic melanoma patients.

Methods:

CD73 expression was assessed by immunohistochemistry in metastatic melanomas from 114 patients. Immunostainings were evaluated in tumor cells (TC) (percentage, intensity (1-3) and H-score) and in tumor-infiltrating mononuclear cells (TIMC) (percentage).

KEYWORDS:

CD73; ecto-5'-nucleotidase; immunohistochemistry; melanoma; prognosis

Conflict of interest statement

CONFLICTS OF INTEREST The authors have declared no conflicts of interest.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center